Operating Lease, Right-of-Use Asset in USD of Relay Therapeutics, Inc. from Q4 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Relay Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset history and change rate from Q4 2019 to Q3 2025.
  • Relay Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $41,369,000.000, a 22.5% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Relay Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $41,369,000 -$11,988,000 -22.5% 30 Sep 2025 10-Q 06 Nov 2025
Q2 2025 $42,730,000 -$12,193,000 -22.2% 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 $50,136,000 -$6,323,000 -11.2% 31 Mar 2025 10-Q 05 May 2025
Q4 2024 $51,762,000 -$6,207,000 -10.7% 31 Dec 2024 10-Q 06 Nov 2025
Q3 2024 $53,357,000 -$6,096,000 -10.3% 30 Sep 2024 10-Q 06 Nov 2024
Q2 2024 $54,923,000 -$5,988,000 -9.8% 30 Jun 2024 10-Q 06 Aug 2024
Q1 2024 $56,459,000 -$5,885,000 -9.4% 31 Mar 2024 10-Q 02 May 2024
Q4 2023 $57,969,000 -$5,785,000 -9.1% 31 Dec 2023 10-K 26 Feb 2025
Q3 2023 $59,453,000 -$5,700,000 -8.7% 30 Sep 2023 10-Q 02 Nov 2023
Q2 2023 $60,911,000 +$41,083,000 +2.1% 30 Jun 2023 10-Q 08 Aug 2023
Q1 2023 $62,344,000 +$42,035,000 +2.1% 31 Mar 2023 10-Q 04 May 2023
Q4 2022 $63,754,000 +$42,974,000 +2.1% 31 Dec 2022 10-K 22 Feb 2024
Q3 2022 $65,153,000 +$43,914,000 +2.1% 30 Sep 2022 10-Q 03 Nov 2022
Q2 2022 $19,828,000 -$1,860,000 -8.6% 30 Jun 2022 10-Q 04 Aug 2022
Q1 2022 $20,309,000 -$1,818,000 -8.2% 31 Mar 2022 10-Q 05 May 2022
Q4 2021 $20,780,000 -$1,799,000 -8% 31 Dec 2021 10-K 23 Feb 2023
Q3 2021 $21,239,000 -$1,135,000 -5.1% 30 Sep 2021 10-Q 10 Nov 2021
Q2 2021 $21,688,000 -$1,090,000 -4.8% 30 Jun 2021 10-Q 12 Aug 2021
Q1 2021 $22,127,000 31 Mar 2021 10-Q 13 May 2021
Q4 2020 $22,579,000 -$981,000 -4.2% 31 Dec 2020 10-K 24 Feb 2022
Q3 2020 $22,374,000 30 Sep 2020 10-Q 12 Nov 2020
Q2 2020 $22,778,000 30 Jun 2020 10-Q 27 Aug 2020
Q4 2019 $23,560,000 31 Dec 2019 10-K 25 Mar 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.